|Project Title||Generation of Humanized Single Gene- Encoded Antibodies, with Varied Effector Functions for Direct Use as Anti- Tumor Reagents, and for Production of Immunoliposomes: DESICLON and TRANSEXPRESS|
|Project Type||Contained Use|
|Name of Institution||National Institute of Molecular Biology and Biotechnology (NIMBB), UP Diliman, Quezon City|
|Cooperating Institution||National Institutes of Health|
|Supervising IBC||UP Diliman-IBC|
|Project Leader(s)||Ameurfina D. Santos, Associate Professor 5|
|Experimental Facility/Site||IRRI, Philippines|
|Purpose / Objectives||To develop engineered, humanized antibodies for cancer therapy and diagnosis.|
|Biosafety measures||Biosafety Level 1 (BL1)|
|Conditions for Approval||1. The required level of containment for the proposed activities is BL2.
2. The activities should only be carried out once the BL2 facility is completed.
3. UP Diliman- IBC shall review the design and inspect the facility to ensure that it conforms with the standard set for BL2 containment.
4. Personnel working on project should have a baseline level, zero collected before the experiments Actually takes place.
|Date of Approval||1999-11-03|
|Subject||Request of Dr. Elma Llaguno for proposal endorsement|
|Requesting Party||Dr. Elma Llaguno, Chairman, UP Diliman IBC|
|Action of NCBP||Approved for implementation|